Literature DB >> 15452237

Clonal selection for transcriptionally active viral oncogenes during progression to cancer.

Brian A Van Tine1, John C Kappes, N Sanjib Banerjee, Judith Knops, Lilin Lai, Renske D M Steenbergen, Chris L J M Meijer, Peter J F Snijders, Pamela Chatis, Thomas R Broker, Phillip T Moen, Louise T Chow.   

Abstract

Primary keratinocytes immortalized by human papillomaviruses (HPVs), along with HPV-induced cervical carcinoma cell lines, are excellent models for investigating neoplastic progression to cancer. By simultaneously visualizing viral DNA and nascent viral transcripts in interphase nuclei, we demonstrated for the first time a selection for a single dominant papillomavirus transcription center or domain (PVTD) independent of integrated viral DNA copy numbers or loci. The PVTD did not associate with several known subnuclear addresses but was almost always perinucleolar. Silent copies of the viral genome were activated by growth in the DNA methylation inhibitor 5-azacytidine. HPV-immortalized keratinocytes supertransduced with HPV oncogenes and selected for marker gene coexpression underwent crisis, and the surviving cells transcribed only the newly introduced genes. Thus, transcriptional selection in response to environmental changes is a dynamic process to achieve optimal gene expression for cell survival. This phenomenon may be critical in clonal selection during carcinogenesis. Examination of HPV-associated cancers supports this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452237      PMCID: PMC521852          DOI: 10.1128/JVI.78.20.11172-11186.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes.

Authors:  R Klaes; S M Woerner; R Ridder; N Wentzensen; M Duerst; A Schneider; B Lotz; P Melsheimer; M von Knebel Doeberitz
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

Review 2.  Genetic instability and darwinian selection in tumours.

Authors:  D P Cahill; K W Kinzler; B Vogelstein; C Lengauer
Journal:  Trends Cell Biol       Date:  1999-12       Impact factor: 20.808

Review 3.  Macromolecular domains within the cell nucleus.

Authors:  D L Spector
Journal:  Annu Rev Cell Biol       Date:  1993

4.  Methylation sensitivity of the enhancer from the human papillomavirus type 16.

Authors:  H J List; V Patzel; U Zeidler; A Schopen; G Rühl; J Stollwerk; G Klock
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

Review 5.  The type I growth factor receptors in human breast cancer.

Authors:  T Rajkumar; W J Gullick
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

6.  The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID.

Authors:  S H Tan; L E Leong; P A Walker; H U Bernard
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

7.  Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis.

Authors:  S Jeon; P F Lambert
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes.

Authors:  S Cheng; D C Schmidt-Grimminger; T Murant; T R Broker; L T Chow
Journal:  Genes Dev       Date:  1995-10-01       Impact factor: 11.361

9.  Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements.

Authors:  G Dong; T R Broker; L T Chow
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

Authors:  R Jüttermann; E Li; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

View more
  46 in total

Review 1.  Papillomavirus genome structure, expression, and post-transcriptional regulation.

Authors:  Zhi-Ming Zheng; Carl C Baker
Journal:  Front Biosci       Date:  2006-09-01

2.  High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia.

Authors:  Tolga Turan; Mina Kalantari; Kate Cuschieri; Heather A Cubie; Hanne Skomedal; Hans-Ulrich Bernard
Journal:  Virology       Date:  2006-12-18       Impact factor: 3.616

3.  Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population.

Authors:  Lisa Mirabello; Chang Sun; Arpita Ghosh; Ana C Rodriguez; Mark Schiffman; Nicolas Wentzensen; Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Attila Lorincz; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2012-03-23       Impact factor: 13.506

4.  In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis.

Authors:  Elizabeth Gray; Mark R Pett; Dawn Ward; David M Winder; Margaret A Stanley; Ian Roberts; Cinzia G Scarpini; Nicholas Coleman
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

Review 5.  Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogen.

Authors:  Kelly M Robinson; Julie C Dunning Hotopp
Journal:  Cancer Lett       Date:  2014-06-21       Impact factor: 8.679

6.  Integration of the full-length HPV16 genome in cervical cancer and Caski and Siha cell lines and the possible ways of HPV integration.

Authors:  Feng Xu; Meng Cao; Qinfeng Shi; Hongwei Chen; Yili Wang; Xu Li
Journal:  Virus Genes       Date:  2015-02-10       Impact factor: 2.332

7.  Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone.

Authors:  Douglas R Hurst; Alka Mehta; Blake P Moore; Pushkar A Phadke; William J Meehan; Mary Ann Accavitti; Lalita A Shevde; James E Hopper; Yi Xie; Danny R Welch; Rajeev S Samant
Journal:  Biochem Biophys Res Commun       Date:  2006-08-10       Impact factor: 3.575

8.  Dynamic localization of the human papillomavirus type 11 origin binding protein E2 through mitosis while in association with the spindle apparatus.

Authors:  Luan D Dao; Aaron Duffy; Brian A Van Tine; Shwu-Yuan Wu; Cheng-Ming Chiang; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

9.  Kinetics of metastatic breast cancer cell trafficking in bone.

Authors:  Pushkar A Phadke; Robyn R Mercer; John F Harms; Yujiang Jia; Andra R Frost; Jennifer L Jewell; Karen M Bussard; Shakira Nelson; Cynthia Moore; John C Kappes; Carol V Gay; Andrea M Mastro; Danny R Welch
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

10.  BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process.

Authors:  Pushkar A Phadke; Kedar S Vaidya; Kevin T Nash; Douglas R Hurst; Danny R Welch
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.